DK1350109T3 - Markör for betændelsestilstande - Google Patents
Markör for betændelsestilstandeInfo
- Publication number
- DK1350109T3 DK1350109T3 DK02707438T DK02707438T DK1350109T3 DK 1350109 T3 DK1350109 T3 DK 1350109T3 DK 02707438 T DK02707438 T DK 02707438T DK 02707438 T DK02707438 T DK 02707438T DK 1350109 T3 DK1350109 T3 DK 1350109T3
- Authority
- DK
- Denmark
- Prior art keywords
- marker
- inflammatory conditions
- pregnancy
- plasma protein
- acute coronary
- Prior art date
Links
- 230000004968 inflammatory condition Effects 0.000 title abstract 2
- 239000003550 marker Substances 0.000 title abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 108030001694 Pappalysin-1 Proteins 0.000 abstract 1
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Rehabilitation Therapy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nuclear Medicine (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/760,376 US6500630B2 (en) | 2001-01-12 | 2001-01-12 | Marker for inflammatory conditions |
PCT/US2002/000762 WO2002056015A1 (en) | 2001-01-12 | 2002-01-11 | Marker for inflammatory conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1350109T3 true DK1350109T3 (da) | 2009-08-31 |
Family
ID=25058918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02707438T DK1350109T3 (da) | 2001-01-12 | 2002-01-11 | Markör for betændelsestilstande |
Country Status (11)
Country | Link |
---|---|
US (9) | US6500630B2 (da) |
EP (2) | EP1350109B1 (da) |
JP (3) | JP4338972B2 (da) |
AT (1) | ATE431551T1 (da) |
AU (1) | AU2002241845B2 (da) |
CA (1) | CA2434512C (da) |
DE (1) | DE60232303D1 (da) |
DK (1) | DK1350109T3 (da) |
ES (1) | ES2324767T3 (da) |
PT (1) | PT1350109E (da) |
WO (1) | WO2002056015A1 (da) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2464121C (en) * | 2000-10-20 | 2013-08-13 | Como Biotech Aps | Pregnancy-associated plasma protein-a2 (papp-a2) |
US6500630B2 (en) * | 2001-01-12 | 2002-12-31 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
DE60200248T2 (de) * | 2002-08-01 | 2005-01-27 | Mtm Laboratories Ag | Verfahren für Lösung-basierte Diagnose |
WO2004046722A2 (de) * | 2002-11-16 | 2004-06-03 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
EP1530047A1 (en) * | 2003-11-07 | 2005-05-11 | Roche Diagnostics GmbH | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease |
PT1882946E (pt) * | 2003-12-23 | 2010-04-21 | Roche Diagnostics Gmbh | Método para avaliar artrite reumatóide através da medição de anti-ccp e interleucina 6 |
EP1709448B1 (en) * | 2004-01-28 | 2008-10-22 | Turun Yliopisto | Improved method for diagnosing acute coronary syndrome |
US7608458B2 (en) * | 2004-02-05 | 2009-10-27 | Medtronic, Inc. | Identifying patients at risk for life threatening arrhythmias |
CA2554836A1 (en) * | 2004-02-05 | 2005-08-25 | Medtronic, Inc. | Methods and apparatus for identifying patients at risk for life threatening arrhythmias |
US20050287574A1 (en) * | 2004-06-23 | 2005-12-29 | Medtronic, Inc. | Genetic diagnostic method for SCD risk stratification |
US8027791B2 (en) * | 2004-06-23 | 2011-09-27 | Medtronic, Inc. | Self-improving classification system |
US8335652B2 (en) * | 2004-06-23 | 2012-12-18 | Yougene Corp. | Self-improving identification method |
JP2008545139A (ja) * | 2005-06-29 | 2008-12-11 | ルールズ−ベースド メディスン,インコーポレーテッド | 急性冠症候群の診断方法及び診断キット |
NZ568992A (en) | 2005-11-17 | 2012-01-12 | Biogen Idec Inc | Platelet aggregation assays comprising platelet activiating agents and agents that cross-links the CD40L-binding moiety |
US20100310461A1 (en) * | 2007-04-18 | 2010-12-09 | Biochromix Pharma Ab | Binding of pathological forms of proteins using conjugated polyelectrolytes |
US20100310462A1 (en) * | 2007-04-18 | 2010-12-09 | Biochromix Ab | Binding of pathological forms of proteins using conjugated polyelectrolytes |
ATE486135T1 (de) * | 2007-07-20 | 2010-11-15 | Univ Liege | Kombination aus verfahren zur sequentiellen messung (1.) der enzymatisch aktiven fraktion und (2.) der gesamtmenge eines enzyms |
WO2009064970A1 (en) * | 2007-11-14 | 2009-05-22 | Medtronic, Inc. | Genetic markers for scd or sca therapy selection |
US20110143956A1 (en) * | 2007-11-14 | 2011-06-16 | Medtronic, Inc. | Diagnostic Kits and Methods for SCD or SCA Therapy Selection |
US20100056873A1 (en) * | 2008-08-27 | 2010-03-04 | Allen Paul G | Health-related signaling via wearable items |
US8130095B2 (en) | 2008-08-27 | 2012-03-06 | The Invention Science Fund I, Llc | Health-related signaling via wearable items |
US8284046B2 (en) | 2008-08-27 | 2012-10-09 | The Invention Science Fund I, Llc | Health-related signaling via wearable items |
US8094009B2 (en) | 2008-08-27 | 2012-01-10 | The Invention Science Fund I, Llc | Health-related signaling via wearable items |
US8125331B2 (en) | 2008-08-27 | 2012-02-28 | The Invention Science Fund I, Llc | Health-related signaling via wearable items |
US20100081928A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Histological Facilitation systems and methods |
US20100317006A1 (en) * | 2009-05-12 | 2010-12-16 | Medtronic, Inc. | Sca risk stratification by predicting patient response to anti-arrhythmics |
FI20095733A0 (fi) | 2009-06-29 | 2009-06-29 | Hytest Oy | IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä |
RU2548710C2 (ru) * | 2009-09-17 | 2015-04-20 | Ф.Хоффманн-Ля Рош Аг | Мультимаркерная панель для гипертрофии левого желудочка |
FI20115367A0 (fi) | 2011-04-15 | 2011-04-15 | Hytest Oy | Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja |
US20150080738A1 (en) * | 2011-08-16 | 2015-03-19 | The General Hospital Corporation | Apparatus, method, and computer-accessible medium for determining antigen immunoreactivity in tissue |
CN106460062A (zh) | 2014-05-05 | 2017-02-22 | 美敦力公司 | 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物 |
US11143659B2 (en) | 2015-01-27 | 2021-10-12 | Arterez, Inc. | Biomarkers of vascular disease |
RU2646490C1 (ru) * | 2016-09-16 | 2018-03-05 | Гюзелия Хатыбулловна Каюмова | Способ прогнозирования летальности у пациентов с инфарктом миокарда |
EP3662480A4 (en) | 2017-08-04 | 2021-05-19 | BillionToOne, Inc. | TARGET-ASSOCIATED MOLECULES FOR CHARACTERIZATION IN CONNECTION WITH BIOLOGICAL TARGETS |
US11519024B2 (en) * | 2017-08-04 | 2022-12-06 | Billiontoone, Inc. | Homologous genomic regions for characterization associated with biological targets |
KR102109850B1 (ko) * | 2017-08-21 | 2020-05-13 | 한양대학교 산학협력단 | 염증의 유무 예측을 위한 바이오마커 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US525641A (en) * | 1894-09-04 | Weather-strip | ||
US5039521A (en) * | 1989-01-11 | 1991-08-13 | Hyal Pharmaceutical Corporation | Immune cell proliferation inhibitors |
US5324502A (en) * | 1992-04-02 | 1994-06-28 | Purdue Research Foundation | Radiopharmaceuticals for imaging the heart |
AU5355094A (en) * | 1992-10-14 | 1994-05-09 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
WO1994021686A1 (en) * | 1993-03-19 | 1994-09-29 | Northern Sydney Area Health Service | Papp-a, its immunodetection and uses |
ATE458499T1 (de) * | 1995-06-07 | 2010-03-15 | Immunomedics Inc | Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort |
US6331286B1 (en) * | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
AU5596298A (en) | 1996-12-09 | 1998-07-03 | Cor Therapeutics, Inc. | Integrin antagonists |
PT1003501E (pt) | 1997-04-02 | 2005-07-29 | Brigham & Womens Hospital | Utilizacao de um agente para reduzir o risco de doencas cardiovasculares |
DE19757250A1 (de) | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
CA2367360C (en) | 1999-03-15 | 2011-08-09 | Michael Toft Overgaard | Insulin-like growth factor binding protein-4 protease |
US7115382B1 (en) * | 1999-03-15 | 2006-10-03 | Mayo Foundation For Medical Education And Research | Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex |
US6500630B2 (en) * | 2001-01-12 | 2002-12-31 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
JP4251617B2 (ja) | 2003-03-10 | 2009-04-08 | キヤノン株式会社 | 電子機器 |
US20060063162A1 (en) * | 2004-09-23 | 2006-03-23 | Deng David X | Biological marker for inflammation |
-
2001
- 2001-01-12 US US09/760,376 patent/US6500630B2/en not_active Expired - Lifetime
-
2002
- 2002-01-11 ES ES02707438T patent/ES2324767T3/es not_active Expired - Lifetime
- 2002-01-11 EP EP02707438A patent/EP1350109B1/en not_active Expired - Lifetime
- 2002-01-11 EP EP09006384A patent/EP2081026A1/en not_active Withdrawn
- 2002-01-11 WO PCT/US2002/000762 patent/WO2002056015A1/en active Application Filing
- 2002-01-11 AU AU2002241845A patent/AU2002241845B2/en not_active Ceased
- 2002-01-11 AT AT02707438T patent/ATE431551T1/de active
- 2002-01-11 JP JP2002556219A patent/JP4338972B2/ja not_active Expired - Fee Related
- 2002-01-11 DE DE60232303T patent/DE60232303D1/de not_active Expired - Lifetime
- 2002-01-11 DK DK02707438T patent/DK1350109T3/da active
- 2002-01-11 PT PT02707438T patent/PT1350109E/pt unknown
- 2002-01-11 CA CA2434512A patent/CA2434512C/en not_active Expired - Lifetime
- 2002-07-31 US US10/210,339 patent/US6699675B2/en not_active Expired - Lifetime
-
2004
- 2004-01-29 US US10/767,666 patent/US20040197844A1/en not_active Abandoned
-
2005
- 2005-02-22 US US11/062,400 patent/US20050136498A1/en not_active Abandoned
- 2005-10-18 US US11/254,224 patent/US20060110773A1/en not_active Abandoned
-
2006
- 2006-09-05 US US11/516,020 patent/US20070065879A1/en not_active Abandoned
-
2009
- 2009-02-20 US US12/389,983 patent/US7723049B2/en not_active Expired - Fee Related
- 2009-04-21 JP JP2009102875A patent/JP4610660B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-24 US US12/785,893 patent/US7939280B2/en not_active Expired - Lifetime
- 2010-08-30 JP JP2010191857A patent/JP5226749B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-09 US US13/103,889 patent/US8323913B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2002241845B2 (en) | 2006-11-09 |
US8323913B2 (en) | 2012-12-04 |
US20020132278A1 (en) | 2002-09-19 |
DE60232303D1 (de) | 2009-06-25 |
JP4338972B2 (ja) | 2009-10-07 |
US7939280B2 (en) | 2011-05-10 |
US6699675B2 (en) | 2004-03-02 |
JP2009198510A (ja) | 2009-09-03 |
WO2002056015A1 (en) | 2002-07-18 |
US20090197342A1 (en) | 2009-08-06 |
EP1350109B1 (en) | 2009-05-13 |
US20070065879A1 (en) | 2007-03-22 |
JP2004531696A (ja) | 2004-10-14 |
US20040197844A1 (en) | 2004-10-07 |
ES2324767T3 (es) | 2009-08-14 |
JP2010281833A (ja) | 2010-12-16 |
US7723049B2 (en) | 2010-05-25 |
CA2434512A1 (en) | 2002-07-18 |
EP1350109A1 (en) | 2003-10-08 |
US20060110773A1 (en) | 2006-05-25 |
JP5226749B2 (ja) | 2013-07-03 |
CA2434512C (en) | 2010-05-11 |
ATE431551T1 (de) | 2009-05-15 |
US20030003521A1 (en) | 2003-01-02 |
EP1350109A4 (en) | 2004-08-18 |
US6500630B2 (en) | 2002-12-31 |
PT1350109E (pt) | 2009-06-30 |
US20050136498A1 (en) | 2005-06-23 |
US20100285510A1 (en) | 2010-11-11 |
US20110212024A1 (en) | 2011-09-01 |
EP2081026A1 (en) | 2009-07-22 |
JP4610660B2 (ja) | 2011-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1350109T3 (da) | Markör for betændelsestilstande | |
NO2020005I1 (no) | ustekinumab. Forlenget SPC | |
ATE286049T1 (de) | Pyridazinonaldose reductase inhibitoren | |
DE60233731D1 (de) | Werkstück-positioniervorrichtung | |
DE60216839D1 (de) | Leistungsverstärker | |
ATE420640T1 (de) | Fab-i-inhibitoren | |
DE50212025D1 (de) | Lösungen organischer halbleiter | |
DE50211354D1 (de) | Transportwagen | |
DE50113812D1 (de) | Explosivstoffgetriebene RF-Strahlenquelle | |
ATE502118T1 (de) | Amplifizierungsverfahren | |
DE60229592D1 (de) | Radlager | |
FR2845917B1 (fr) | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire | |
ATE429431T1 (de) | 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren | |
DE50113261D1 (de) | Linearwälzlager | |
DE60103725D1 (de) | Laserquelle | |
NO20006447D0 (no) | Bölgeleder-laserkilde | |
DE60229669D1 (de) | X-2 inhibitoren | |
ATE535775T1 (de) | Präzisionsdendrometer | |
DE60216461D1 (de) | Stabilitätsverbesserter multistufe-leistungsverstärker | |
DE60136750D1 (de) | Werkstückträger | |
DE60220872D1 (de) | Linearlagerführung | |
BRPI0307722A2 (pt) | microorganismo envolvido | |
DE50209630D1 (de) | Drehmaschine | |
DE50201269D1 (de) | Radiallager | |
FR2831844B3 (fr) | Piece usinee par transformation |